touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer.
The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO Annual Meeting.
Citation: J Clin Oncol 39, 2021 (suppl 15; abstr 3584)
DOI: 10.1200/JCO.2021.39.15_suppl.3584
Questions
1. What is favezelimab (MK4280) and its mechanism of action? (00:14-00:39)
2. What was the rationale for using favezelimab in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer that had progressed on two or more prior therapies? (00:39-01:33)
3. Could you give us an overview of the phase I study and its findings? (01:33-03:08)
4. Which patients had the best response to this combination? (03:08-03:30)
5. What will be the next steps in the clinical development of favezelimab in this treatment setting? (03:30-04:08)
6. What do you think is the most important aspect to consider with regards to immunotherapy in this patient subset? (04:08-04:42)
Disclosures: Research: Novartis, Roche, Thermo Fisher, AstraZeneca, Taiho, BeiGene. Consultant/Advisor: Roche/Genentech, F.Hoffmann/La Roche, Ellipses Pharma, Neomed Therapeutics1 Inc, Boehringer Ingelheim, Janssen Global Services, SeaGen, TFS, Alkermes, Thermo Fisher, Bristol-Mayers Squibb, MabDiscovery, Anaveon. Travel Grants: Bristol-Mayers Squibb, Merck Sharp & Dohme, Menarini, Glycotope. Speakers Bureau: Merck Sharp & Dohme, Roche, Thermo Fisher, Lilly. Clinical Trials PI or Co-PI (Institution): Affimed Gmbh, Amgen SA, Anaveon AG, AstraZeneca AB, Biontech Gmbh, Catalym Gmbh, Cytomx, F.Hoffmann, La Roche Ltd, F-Star Beta Limited, Genentech Inc, Genmab B.V., Hutchison Medipharma Limited, Icon, Imcheck Therapeutics, Immunocore Ltd, Janssen-Cilag SA, Medimmune Llc, Merck Kgga, Novartis Farmacéutica, S.A, Peptomyc, Ribon Therapeutics, Roche Farma SA, Seattle Genetics Inc, Symphogen A/S, Taiho Pharma Usa Inc.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Helen Fowler.
Filmed in coverage of the 2021 ASCO Annual Meeting.
